Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for five companies, including Deyi Group, which is seeking to list on the Hong Kong Stock Exchange. The CSRC has requested clarifications on various aspects of the company's operations and shareholder structure [1][2][3]. Group 1 - The CSRC requires Deyi Group to clarify the identification of its controlling shareholders and whether it plans to continue pursuing an A-share listing [1][2]. - Deyi Group must provide details on the share transfer prices and their legality over the past 12 months, along with a legal opinion on the compliance of its establishment and share changes [1][2]. - The company is asked to explain the progress of share transfers related to Shanghai Huiyu Medical Technology Partnership and any changes to its shareholding structure before and after the proposed "full circulation" [1][2]. Group 2 - The CSRC has requested information on the progress of identifying state-owned shareholders and whether the company's business involves foreign investment restrictions [2]. - Deyi Group must disclose its previous A-share listing application details and any plans to continue pursuing this listing, including potential impacts on the current issuance [2]. - The company is required to clarify whether it operates any apps or platforms that collect personal information, detailing the scale and usage of such data [2][3]. Group 3 - Deyi Group is recognized as a global leader in innovative radiosurgery solutions, with its core product, CybeRay, being the first real-time image-guided gamma radiosurgery system approved by both the FDA and the National Medical Products Administration of China [3]. - The company is also developing its flagship product, TaiChiRT Pro, which is the first integrated X/gamma radiation therapy system to receive breakthrough medical device designation from the FDA [3].

| | 第1輪競資 | 第2輪融資 | 第3輪融資 | 第4輪融資 | 第5輪融資 | 第6輪融資 | 第6+輪融資 | | --- | --- | --- | --- | --- | --- | --- | --- | | 協議日期 | 2019年1月30日 | 2019年7月31日 | 2020年2月24日 | 2020年5月16日 | 2020年6月24日 | 2022年3月17日 | 由2022年12月29日至 | | | | | | | | | 2024年2月5日 | | 支付全部代價的日期 | 2019年2月2日 | 2019年8月23日 | 2020年2月26日 | 2020年5月28日 | 2020年6月30日 | 2022年7月14日 | 2024年2月16日 | | 每股股份概約成本 . | 人民幣21.68元 | 人民幣21.80元 | 人民幣25.80元 | 人民幣26.25元 | 人民幣26.54元 | 人民幣33.46元 | 人民幣33.53元 | | 認購的註冊資本 / 股份金額 ... | 922,722.03 | 5.504.875.75 | 5.813,272 | 4.57 ...